{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:46:46Z","timestamp":1791524806038,"version":"4.3.4"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.12939","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:01:42Z","timestamp":1652958102000},"page":"e2212939","source":"Crossref","is-referenced-by-count":84,"title":["Comparison of Amitriptyline and US Food and Drug Administration\u2013Approved Treatments for Fibromyalgia"],"prefix":"10.1001","volume":"5","author":[{"given":"Hussein M.","family":"Farag","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"},{"name":"Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"},{"name":"Biostatistics and Research Decision Sciences and Health Economics and Decision Sciences, Merck & Co, North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihtisham","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"},{"name":"Health Economics and Outcomes Research Neuroscience, AbbVie, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"Doucette","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tewodros","family":"Eguale","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston"},{"name":"Department of Medicine, McGill University Health Centre, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"zoi220381r1","doi-asserted-by":"publisher","first-page":"15022","DOI":"10.1038\/nrdp.2015.22","article-title":"Fibromyalgia.","volume":"1","author":"H\u00e4user","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"zoi220381r2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia.","volume":"17","author":"Queiroz","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"zoi220381r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults.","volume":"12","author":"Moore","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi220381r4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population.","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"20","key":"zoi220381r6","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"issue":"7","key":"zoi220381r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"11","key":"zoi220381r8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi220381r9","first-page":"928","article-title":"Two contributions to understanding of the \u201cfibrositis\u201d syndrome.","volume":"28","author":"Smythe","year":"1977-1978","journal-title":"Bull Rheum Dis"},{"issue":"1","key":"zoi220381r10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0049-0172(81)90096-2","article-title":"Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls.","volume":"11","author":"Yunus","year":"1981","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"zoi220381r11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee.","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"5","key":"zoi220381r12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"zoi220381r13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia.","volume":"38","author":"Wolfe","year":"2011","journal-title":"J Rheumatol"},{"issue":"3","key":"zoi220381r14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 revisions to the 2010\/2011 fibromyalgia diagnostic criteria.","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"zoi220381r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"zoi220381r16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"zoi220381r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool.","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"zoi220381r18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers.","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"zoi220381r19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/rssb.1993.55.issue-1","article-title":"Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods.","volume":"55","author":"Smith","year":"1993","journal-title":"J R Stat Soc B"},{"issue":"24","key":"zoi220381r22","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline.","volume":"24","author":"Abrams","year":"2005","journal-title":"Stat Med"},{"issue":"247","key":"zoi220381r24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/01621459.1949.10483310","article-title":"The Monte Carlo method.","volume":"44","author":"Metropolis","year":"1949","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"zoi220381r25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences.","volume":"7","author":"Gelman","year":"1992","journal-title":"Stat Sci"},{"issue":"434","key":"zoi220381r26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/01621459.1996.10476956","article-title":"Markov chain Monte Carlo convergence diagnostics: a comparative review.","volume":"91","author":"Cowles","year":"1996","journal-title":"J Am Stat Assoc"},{"issue":"7-8","key":"zoi220381r27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"4","key":"zoi220381r28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package.","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata J"},{"issue":"10","key":"zoi220381r29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.7326\/M15-2521","article-title":"Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials.","volume":"164","author":"Trinquart","year":"2016","journal-title":"Ann Intern Med"},{"key":"zoi220381r30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS\u2014a bayesian modelling framework: concepts, structure, and extensibility.","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"issue":"10","key":"zoi220381r31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA.","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"7109","key":"zoi220381r32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"zoi220381r33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"issue":"5","key":"zoi220381r34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study.","volume":"29","author":"Carette","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"11","key":"zoi220381r35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/(ISSN)1529-0131","article-title":"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia.","volume":"29","author":"Goldenberg","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"2-3","key":"zoi220381r36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000119138","article-title":"Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia.","volume":"30","author":"Kempenaers","year":"1994","journal-title":"Neuropsychobiology"},{"issue":"1","key":"zoi220381r37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial.","volume":"37","author":"Carette","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"3","key":"zoi220381r38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1300\/J094v04n03_05","article-title":"A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia.","volume":"4","author":"Ginsberg","year":"1996","journal-title":"J Musculoskeletal Pain"},{"issue":"12","key":"zoi220381r39","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/37.12.1279","article-title":"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.","volume":"37","author":"Hannonen","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"6","key":"zoi220381r40","first-page":"697","article-title":"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures.","volume":"19","author":"Heymann","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"zoi220381r41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0022-3956(02)00003-1","article-title":"The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial.","volume":"36","author":"Fors","year":"2002","journal-title":"J Psychiatr Res"},{"issue":"1","key":"zoi220381r42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rbp.2013.01.004","article-title":"Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial.","volume":"35","author":"Braz","year":"2013","journal-title":"Braz J Psychiatry"},{"issue":"9","key":"zoi220381r43","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/(ISSN)1529-0131","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1-3","key":"zoi220381r44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"key":"zoi220381r45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IJGM","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.","volume":"1","author":"Chappell","year":"2008","journal-title":"Int J Gen Med"},{"issue":"3","key":"zoi220381r46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"issue":"5","key":"zoi220381r47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.","volume":"25","author":"Chappell","year":"2009","journal-title":"Clin J Pain"},{"issue":"12","key":"zoi220381r48","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3899\/jrheum.100365","article-title":"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.","volume":"37","author":"Arnold","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"zoi220381r49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/AJP.0b013e3182510295","article-title":"Efficacy and safety of duloxetine 30 mg\/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.","volume":"28","author":"Arnold","year":"2012","journal-title":"Clin J Pain"},{"key":"zoi220381r50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13075-015-0718-y","article-title":"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients.","volume":"17","author":"Murakami","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"zoi220381r51","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8","key":"zoi220381r52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1526-4637.2007.00332.x","article-title":"The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia.","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med"},{"issue":"9","key":"zoi220381r53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"issue":"3","key":"zoi220381r54","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"issue":"12","key":"zoi220381r55","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3899\/jrheum.110569","article-title":"An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia.","volume":"38","author":"Pauer","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"zoi220381r56","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar4056","article-title":"A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia.","volume":"14","author":"Ohta","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"19","key":"zoi220381r57","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/(ISSN)1099-1077","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.","volume":"19","author":"Vitton","year":"2004","journal-title":"Hum Psychopharmacol"},{"issue":"10","key":"zoi220381r58","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia.","volume":"32","author":"Gendreau","year":"2005","journal-title":"J Rheumatol"},{"issue":"11","key":"zoi220381r59","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.","volume":"30","author":"Clauw","year":"2008","journal-title":"Clin Ther"},{"issue":"2","key":"zoi220381r60","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.","volume":"36","author":"Mease","year":"2009","journal-title":"J Rheumatol"},{"issue":"9","key":"zoi220381r61","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/art.27559","article-title":"Efficacy and safety of milnacipran 100 mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.","volume":"62","author":"Arnold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi220381r62","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3899\/jrheum.090884","article-title":"A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.","volume":"37","author":"Branco","year":"2010","journal-title":"J Rheumatol"},{"issue":"2","key":"zoi220381r63","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Med"},{"issue":"8","key":"zoi220381r64","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jpain.2015.04.010","article-title":"Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial.","volume":"16","author":"Staud","year":"2015","journal-title":"J Pain"},{"key":"zoi220381r65","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2147\/DDDT","article-title":"Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study.","volume":"12","author":"Pickering","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"zoi220381r66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3899\/jrheum.101025","article-title":"Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.","volume":"38","author":"Branco","year":"2011","journal-title":"J Rheumatol"},{"issue":"9","key":"zoi220381r67","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia.","volume":"38","author":"Carette","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"7","key":"zoi220381r68","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3899\/jrheum.141196","article-title":"Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study.","volume":"42","author":"Arnold","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"zoi220381r69","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5664\/jcsm.5400","article-title":"The effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study.","volume":"12","author":"Ahmed","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"zoi220381r70","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","article-title":"Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.","volume":"50","author":"H\u00e4user","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"10128","key":"zoi220381r71","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"zoi220381r72","article-title":"Fibromyalgia and depression.","volume":"2012","author":"Gracely","year":"2012","journal-title":"Pain Res Treat"},{"issue":"6","key":"zoi220381r73","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-201249","article-title":"Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis.","volume":"72","author":"N\u00fcesch","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi220381r74","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/j.pain.0000000000001849","article-title":"John D. Loeser Award Lecture: size does matter, but it isn\u2019t everything: the challenge of modest treatment effects in chronic pain clinical trials.","volume":"161","author":"Smith","year":"2020","journal-title":"Pain"},{"key":"zoi220381r20","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian Data Analysis","author":"Gelman","year":"2013","edition":"3rd ed"},{"key":"zoi220381r21","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"key":"zoi220381r23","author":"Jonas","year":"2013"},{"key":"zoi220381r5","unstructured":"Frost & Sullivan Health and Life Sciences. Assessment of the U.S. fibromyalgia market in support of S1 filing (Phase 2). 2010. Accessed July 20, 2021. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1430306\/000101376211002697\/exh9902.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2792390\/farag_2022_oi_220381_1651906271.41309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:01:54Z","timestamp":1652958114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2792390"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.12939","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}